Cambridge Investment Research Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-38,017
| Closed | -$9K | – | 4172 |
|
|
2026
Q1 | $9K | Buy |
38,017
+4,200
| +12% | +$1.67K | ﹤0.01% | 3912 |
|
|
2025
Q4 | $14K | Sell |
33,817
-973
| -3% | -$516 | ﹤0.01% | 3800 |
|
|
2025
Q3 | $23K | Buy |
34,790
+3,000
| +9% | +$1.62K | ﹤0.01% | 3687 |
|
|
2025
Q2 | $17K | Buy |
31,790
+6,000
| +23% | +$3.56K | ﹤0.01% | 3584 |
|
|
2025
Q1 | $17K | Hold |
25,790
| – | – | ﹤0.01% | 3468 |
|
|
2024
Q4 | $26K | Hold |
25,790
| – | – | ﹤0.01% | 3412 |
|
|
2024
Q3 | $22K | Buy |
25,790
+300
| +1% | +$220 | ﹤0.01% | 3363 |
|
|
2024
Q2 | $9K | Buy |
25,490
+200
| +0.8% | +$108 | ﹤0.01% | 3295 |
|
|
2024
Q1 | $17K | Sell |
25,290
-5,284
| -17% | -$3.83K | ﹤0.01% | 3271 |
|
|
2023
Q4 | $17K | Sell |
30,574
-280
| -0.9% | -$129 | ﹤0.01% | 3150 |
|
|
2023
Q3 | $19K | Hold |
30,854
| – | – | ﹤0.01% | 3085 |
|
|
2023
Q2 | $40K | Hold |
30,854
| – | – | ﹤0.01% | 3098 |
|
|
2023
Q1 | $54K | Hold |
30,854
| – | – | ﹤0.01% | 3030 |
|
|
2022
Q4 | $97K | Sell |
30,854
-58
| -0.2% | -$225 | ﹤0.01% | 2915 |
|
|
2022
Q3 | $151K | Hold |
30,912
| – | – | ﹤0.01% | 2781 |
|
|
2022
Q2 | $128K | Buy |
30,912
+2,050
| +7% | +$8.87K | ﹤0.01% | 2824 |
|
|
2022
Q1 | $168K | Sell |
28,862
-100
| -0.3% | -$595 | ﹤0.01% | 2921 |
|
|
2021
Q4 | $217K | Sell |
28,962
-542
| -2% | -$4.71K | ﹤0.01% | 2817 |
|
|
2021
Q3 | $266K | Sell |
29,504
-69
| -0.2% | -$682 | ﹤0.01% | 2556 |
|
|
2021
Q2 | $354K | Sell |
29,573
-5,233
| -15% | -$59.2K | ﹤0.01% | 2350 |
|
|
2021
Q1 | $436K | Hold |
34,806
| – | – | ﹤0.01% | 1998 |
|
|
2020
Q4 | $543K | Buy |
34,806
+4,861
| +16% | +$56.9K | ﹤0.01% | 1718 |
|
|
2020
Q3 | $283K | Sell |
29,945
-100
| -0.3% | -$1.08K | ﹤0.01% | 1980 |
|
|
2020
Q2 | $269K | Hold |
30,045
| – | – | ﹤0.01% | 1966 |
|
|
2020
Q1 | $191K | Hold |
30,045
| – | – | ﹤0.01% | 1958 |
|
|
2019
Q4 | $251K | Buy |
30,045
+7,125
| +31% | +$65.5K | ﹤0.01% | 2033 |
|
|
2019
Q3 | $207K | Buy |
22,920
+3,434
| +18% | +$38.5K | ﹤0.01% | 2092 |
|
|
2019
Q2 | $210K | Buy |
19,486
+200
| +1% | +$2.13K | ﹤0.01% | 1973 |
|
|
2019
Q1 | $184K | Buy |
19,286
+2,990
| +18% | +$30.5K | ﹤0.01% | 2094 |
|
|
2018
Q4 | $187K | Buy |
16,296
+5,580
| +52% | +$69.3K | ﹤0.01% | 1939 |
|
|
2018
Q3 | $182K | Buy |
+10,716
| New | +$163K | ﹤0.01% | 2074 |
|
Other funds holding SGMO
Cambridge Investment Research Advisors's SGMO Position: Q2 2026 in Review
Cambridge Investment Research Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2026, closing a stake of 38,017 shares — an estimated $9K sold.
Cambridge Investment Research Advisors first reported a position in SGMO in Q3 2018 and held it in 31 quarters. The position peaked at $543K in Q4 2020. 2 funds tracked by Wall St. Rank hold SGMO as of Q2 2026.
- Cambridge Investment Research Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2026 after selling out during the quarter.
- Cambridge Investment Research Advisors sold 38,017 SANGAMO THERAPEUTICS INC shares in Q2 2026, an estimated $9K.
- Cambridge Investment Research Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q3 2018 and held it in 31 quarters.
- Cambridge Investment Research Advisors's SANGAMO THERAPEUTICS INC position peaked at $543K in Q4 2020.
- 2 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2026.
Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.